Andrew Hopkins is the Founder and Chief Executive of Xyme Ltd, focusing on the development of generative AI for the de novo design of novel enzymes for industrial and climate change applications.
Hopkins is also the Founder and former Chief Executive of Exscientia plc, where he has pioneered the use of artificial intelligence and machine learning to design new medicines. Hopkins led the teams that discovered the first drugs to enter human clinical trials which were designed with the extensive use of machine learning and AI generative methods. For its end-to-end AI-driven precision medicine platform, at Exscientia won the Prix Galien for Digital Health three times (the USA Award in 2022, the UK Award in 2023 and the International Award in 2024). Hopkins was named by TIME Magazine as one of the Top 100 Most Influential People in AI in its inaugural list in 2023.
Hopkins holds an honorary Professorship at the University of Dundee, where he previously held the Chairs of Medicinal Informatics and Translational Biology. He served as the Director of the Scottish Universities Life Science Alliance and co-founded the European Lead Factory. Prior to the University of Dundee, he spent a decade at Pfizer leading various informatics groups. Hopkins received his DPhil in biophysics from the University of Oxford and LLD from the University of Dundee. Hopkins was awarded the Royal Society of Chemistry, Biological and Medicinal Chemistry Sector, Hall of Fame and Medal in 2023.
Professional position
- Honorary Professor, School Of Life Sciences, University of Dundee
- Chief Executive, Xyme Ltd
Subject groups
-
Computer Sciences
Artificial intelligence, machine learning, vision, Databases
-
Astronomy and Physics
Biophysics, Crystallography
-
Chemistry
Chemistry, applied
-
Molecules of Life
Biophysics and structural biology
